Clinical trials: Resistant Major Depression
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny
Depressive Disorder
Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy
The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting…
- Trial name
- NCT05388461
- Testing
- electroconvulsive therapy
- Where
- 2 sites in Norway
- Volunteers
- 600 people
- Sponsor
- Haukeland University Hospital
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in…
- Trial name
- NCT07217223
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Major Depressive Disorder
A Double-blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression
The main treatment option for Treatment Resistant Depression is electroconvulsive therapy (ECT) which is often effective but complicated by cognitive side effects, need for anaesthesia and considerable stigma.
- Trial name
- NCT00402220
- Testing
- TMS
- Where
- Australia
- Volunteers
- 67 people
- Sponsor
- Bayside Health
Depression, Depressive Disorder, Major
Comparing the Efficacy of Accelerated vs. Standard fMRI-guided iTBS in Treating Adolescents Depression
Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS), a type of rTMS, is a very promising new treatment for major depression in adults and…
- Trial name
- NCT06528938
- Testing
- Theta Burst Stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Unipolar Depression
Lamotrigine Augmentation in Resistant Depression
This study is intended to evaluate the efficacy and safety of lamotrigine as an antidepressant augmentation agent in a sample of individuals with major depression and a history of both prior non-response and prospective failure…
- Trial name
- NCT00901407
- Testing
- lamotrigine, paroxetine
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Mitochondrial Function After Ketamine
The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression. the Research Questions are 1.
- Trial name
- NCT07399756
- Testing
- S (+) Ketamine
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression
The present study has been designed to compare the efficacy and safety of augmentation of SSRIs with Amantadine vs Pramipexole vs the recommended Quetiapine augmentation in Treatment-Resistant Depression (TRD) and correlate the…
- Trial name
- APQ-TRD (NCT04936126)
- Testing
- Quetiapine, Amantadine, Pramipexole
- Where
- India
- Volunteers
- 150 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Major Depressive Disorder
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in…
- Trial name
- NCT01260649
- Testing
- ketamine, IV Saline, ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
The purpose of this study is to identify evidence-based guidelines for treating major depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients.
- Trial name
- NCT01699490
- Testing
- Fluoxetine + Valsartan
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Cheng-Kung University Hospital
Major Depressive Disorder
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. Scopolamine infusions produced also a significant improvement in depression that was sustained over time.
- Trial name
- NCT01613820
- Testing
- Ketamine, Scopolamine
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
MRI Studies of Emotion in Depression
The purpose of this study is to research the effects of ketamine on brain function in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT02429011
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment-Resistant Major Depressive Disorder, Major Depressive Disorder
Precision Closed-loop Brain-Computer Interface Neuromodulation for Treatment-Resistant Depression
The goal of this clinical trial is to evaluate whether precision closed-loop neuromodulation treatments can improve depressive symptoms and daily functioning in people with treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT07783906
- Testing
- Closed-loop Deep Brain Stimulation (DBS), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- Volunteers
- 70 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.